Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | Chief Communications Officer | March 16, 2022 | March 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SAB Biotherapeutics, Inc.
Report date March 16, 2022 · Filed March 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.78 · Expires 2032-03-16 | Direct | 16,405 |
Reported balance
After 2022-03-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-16 · Grant · Acquired 16,405 · Balance 16,405 F1: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.
F2: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2022 Filed Mar 19, 2022 01:15 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 16,405 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000899243-22-011662 · doc4.xml · derivative · entry 1 Ullerich Melissa Vera · CIK 0001889813 · Chief Communications Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,405 Underlying: Common Stock · 16,405 shares Expires 2032-03-16 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors. Read SEC document |
| October 22, 2021 Filed Oct 27, 2021 01:48 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEarnout Rights (Restricted Stock Units) · Derivative | 50,988 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-026383 · ownership.xml · derivative · entry 4 Ullerich Melissa Vera · CIK 0001889813 · Chief Communications Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,988 Underlying: Common Stock · 50,988 shares Expires not disclosed F5 · derivative.exercise_price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.] F6 · derivative.exercise_price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period. F5 · price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.] F6 · price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period. F5 · derivative.exercise_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.] F6 · derivative.exercise_date: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period. F5 · derivative.expiration_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.] Read SEC document |
| October 22, 2021 Filed Oct 27, 2021 01:48 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 104,689 | Not disclosed Strike: $1.88 | Not disclosed |
DisclosureSEC source: 0001493152-21-026383 · ownership.xml · derivative · entry 3 Ullerich Melissa Vera · CIK 0001889813 · Chief Communications Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,689 Underlying: Common Stock · 104,689 shares Expires 2031-06-17 F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer"). F4 · price: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, March 29, 2020, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer"). F4 · derivative.exercise_date: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, March 29, 2020, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date. Read SEC document |
| October 22, 2021 Filed Oct 27, 2021 01:48 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 58,161 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0001493152-21-026383 · ownership.xml · derivative · entry 2 Ullerich Melissa Vera · CIK 0001889813 · Chief Communications Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,161 Underlying: Common Stock · 58,161 shares Expires 2028-11-01 F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer"). F3 · price: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, November 1, 2018, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer"). F3 · derivative.exercise_date: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, November 1, 2018, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date. Read SEC document |
| October 22, 2021 Filed Oct 27, 2021 01:48 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 6,979 | Not disclosed Strike: $1.25 | Not disclosed |
DisclosureSEC source: 0001493152-21-026383 · ownership.xml · derivative · entry 1 Ullerich Melissa Vera · CIK 0001889813 · Chief Communications Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,979 Underlying: Common Stock · 6,979 shares Expires 2030-04-27 F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer"). F2 · price: The option is fully vested. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer"). F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.